EWG Elevate’s ADMA Biologics ADMA Stock Holding History

EWG Elevate’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,000	Closed	-$480K	–	122
2024 Q4	$480K	Buy	+28,000	New	+$527K	0.15%	99
2024 Q3	–	Sell	-70,000	Closed	-$783K	–	114
2024 Q2	$783K	Sell	70,000 -30,000	-30%	-$252K	0.29%	74
2024 Q1	$660K	Buy	100,000 +50,000	+100%	+$273K	0.25%	78
2023 Q4	$226K	Buy	50,000 +25,000	+100%	+$92.5K	0.09%	95
2023 Q3	$89.5K	Sell	25,000 -39,000	-61%	-$150K	0.04%	93
2023 Q2	$236K	Sell	64,000 -36,000	-36%	-$133K	0.1%	85
2023 Q1	$331K	Buy	+100,000	New	+$346K	0.14%	66
2022 Q4	–	Sell	-121,000	Closed	-$294K	–	834
2022 Q3	$294K	Buy	121,000 +21,000	+21%	+$50.4K	0.17%	58
2022 Q2	$198K	Hold	100,000	–	–	0.1%	73
2022 Q1	$183K	Buy	+100,000	New	+$156K	0.07%	89

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

EWG Elevate's ADMA Position: Q1 2025 in Review

EWG Elevate sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 28,000 shares — an estimated $480K sold.

EWG Elevate first reported a position in ADMA in Q1 2022 and held it in 10 quarters. The position peaked at $783K in Q2 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

EWG Elevate reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
EWG Elevate sold 28,000 ADMA Biologics shares in Q1 2025, an estimated $480K.
EWG Elevate first reported a position in ADMA Biologics in Q1 2022 and held it in 10 quarters.
EWG Elevate's ADMA Biologics position peaked at $783K in Q2 2024.
347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on EWG Elevate's 13F filing for Q1 2025, filed 10 Apr 2025.